About: http://webisa.webdatacommons.org/319650463

Property	Value
http://www.w3.org/1999/02/22-rdf-syntax-ns#type	http://www.w3.org/ns/prov#Entity
http://www.w3.org/ns/prov#value	shows Tysabri is more effective than Gilenya, so the new drug will go mostly to patients with early, mild MS. But you never no what will happen in the marketplace.
http://www.w3.org/ns/prov#wasQuotedFrom	blogspot.com